Slide 1: Interim results presentation
Interim results presentation for the 6 months ended 30 November 2021 10 February 2022
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by and is the sole responsibility of the directors of Feedback plc (the “Company”). This presentation does not constitute a recommendation or advice regarding the shares of the Company nor a representation that any dealing in those shares is appropriate
Slide 3: Overview
Overview Leading specialist clinical communications platform, well-positioned to capitalise on digital transformation underway in 1 healthcare in the UK and internationally for both human and animal care Growing routes to market with recently launched Bleepa and CareLocker solutions for remote GDPR
Slide 4: Product developments
r Product developments 1 FEEDBACKDIc
Slide 5: Feedback evolution and product rollout
Feedback evolution and product rollout Concept Approval Rollout Products NHS trusts UK veterinary sector NHS - CDCs National TB screening Private hospitals Rest of the world veterinary sector NDHM- health record NHS trusts (legacy product) Research institutions (legacy product) • Following a strateg
Slide 6: Connecting clinicians
Connecting clinicians A leading clinical imaging-based communication platform Safe Patient-specific structure: Removes misidentification risk Ensures information governance compliance Allows case discussion to link to core medical records Secure Zero footprint (no data stored locally on the access d
Slide 7: Expanding the clinical settings
Expanding the clinical settings A specialist tool to enable image transfer from remote settings to the Bleepa platform BleepaBox launched in September 2021, which enables digital images to be acquired by a clinician in rural settings and sent to the Bleepa platform over a mobile network allowing ins
Slide 8: Enhancing clinical access to data
Enhancing clinical access to data A proprietary and patient-centric cloud architecture designed for secure storage of patient records CareLocker launched in September 2021 and enables Bleepa to support care delivery across provider settings in a secure and scalable way Security: Revolutionary GDPR c
Slide 9: Supporting decision making with AI
Supporting decision making with AI • Awarded a place in September 2021 on the NHS national procurement framework for artificial intelligence and imaging • Bleepa enables third party AI tools to be deployed within the app by frontline clinical users for the diagnostic interpretation of medical imagin
Slide 10: H1 operational highlights
Expansion of routes to market with launches of CareLocker and BleepaBox • Estimated total addressable market for product suite in excess of £10 billion globally H1 operational Increased commercialisation both within the NHS and through non-NHS channels • ~9% increase in revenues – reflecting initial
Slide 11: Financial highlights
Financial highlights Revenue(1): increased 9% to £179k (H1 2021: £165k), driven by the Revenue and Sales EBITDA loss initial commercialisation of Bleepa; full year expected to be ahead of market expectations £287 £246 £179 £165 £177 (£916) Sales(2): increased 654% to £246k (H1 2021: £33k) as a highe
Slide 12: Post period highlights
Strong progress towards use of Bleepa and CareLocker in tuberculosis screening opportunity in India: • Partnership with Amazon Web Services to support cloud-based TB screening programme for rural communities in India • Bleepa recently deployed at pilot hospital in Orissa ahead of schedule, overtakin
Slide 13: Significant growth drivers
Significant growth drivers 13
Slide 14: Tuberculosis screening programme in India
Tuberculosis screening programme in India • Partnership with Qure.ai, specialist in AI-powered radiology solutions, announced in September 2021. Qure.ai is in 45+ countries, processing more than 15,000 scans daily • Bleepa can facilitate the upload of in-field images for Qure.ai’s technology to asse
Slide 15: Opportunity to accelerate in NHS: community diagnostic centres (CDCs)
Opportunity to accelerate in NHS : community diagnostic centres (CDCs) NHS England’s ambition is to bring diagnostic investigations closer to patients to reduce the post- COVID elective care backlog and improve the patient journey. This will enable patients to have tests such as imaging, bloods and
Slide 16: Digitally connecting care providers
Digitally connecting care providers • Pilot scheme with Sussex Integrated Care System announced in October 2021, running until March 2022, implementing Bleepa and CareLocker with its community diagnostic centres • Focus on specific CDC clinical pathways such as breathlessness • Present diagnostic in
Slide 17: Partnership with leading veterinary service
Partnership with leading veterinary service • First paid contract in the veterinary sector with CVS, one of the UK’s leading providers of integrated veterinary services, in its equine division • Significant recent progress onboarding 400+ vets, specialists and practice staff to Bleepa • Covering 20+
Slide 18: Outlook
Outlook 1 Growing number of products, routes to markets and end customers 2 Significant opportunities enhanced by partnerships 3 Strong focus on community diagnostic centres in the UK and tuberculosis in India 4 Proven value proposition of technology 18
Slide 19: Appendices
r Appendices 1 FEEDBACKDIc
Slide 20: H1 2022 – income statement
H1 2022 – income statement 6 months 6 months 12 months ending ending ending 31 May 30 November 2021 30 November 2020 2021 (Unaudited) (Unaudited) (Audited) £’000 £’000 £’000 Revenue 179 165 287 Cost of sales (60) (1) (25) Gross profit 119 164 262 Other operating expenses (1,357) (1,082) (2,323) Oper
Slide 21: H1 2022 – balance sheet
H1 2022 – balance sheet 30 November 2021 30 November 2020 31 May 2021 (Unaudited) (Unaudited) (Audited) £’000 £’000 £’000 Property, plant and equipment 11 26 14 Intangible assets 3,079 1,979 2,682 3,090 2,005 2,695 Trade and other receivables 62 94 138 Corporation tax receivable 614 522 767 Cash and
Slide 22: H1 2022 – cashflow statement
H1 2022 – cashflow statement 6 months 6 months 12 months ending ending ending 31 May 30 November 2021 30 November 2020 2021 (Unaudited) (Unaudited) (Audited) £’000 £’000 £’000 Cash flows from operating activities Loss before tax (1,238) (918) (2,060) Adjustments for: Net finance income (0) - (0) Dep
Slide 23: >£10bn opportunity estimated in core target markets
>£10bn opportunity estimated in core target markets Total addressable market analysis 1 2 3 4 5 6 7 8 UK North America EU veterinary Private National TB NDHM – NHS trusts NHS - CDCs veterinary veterinary TOTAL sector hospitals screening health record sector sector Geography UK UK UK EU North America
Slide 24: Supporting decision making with AI
Supporting decision making with AI Integrates third-party artificial intelligence tools to assist with efficient and timely diagnosis • One platform for clinician use providing AI deployment Provides AI providers with the patient data that they • Bleepa charges flat rate commission to AI provider an
Slide 25: Feedback plc Board
Feedback plc Board Prof Rory Shaw, Non-executive Chairman: Dr Thomas Oakley, Chief Executive Officer Ex senior NHS executive, Medical Director since February 2019, previously Radiologist of Healthcare UK, Dept of International and Clinical Entrepreneur Fellow at NHS Trade, and consultant pulmonary p
Slide 26: Feedback Medical Ltd Leadership Team
Feedback Medical Ltd Leadership Team Dr Thomas Oakley, Chief Executive Officer since February 2019, previously Radiologist and Clinical Entrepreneur Fellow at NHS England. Anesh Patel, Chief Financial Mike Hayball, Chief Technology Stephen McAteer, Chief Operating Officer: Chartered Accountant Offic
Slide 27: Company history
Company history • Bleepa gets 1st commercial contract at Royal Berkshire Hospitals NHS Foundation Trust 2021 • Launch of CareLocker • Bleepa achieves veterinary sector contract with CVS and international opportunities via DIT missions • Bleepa adopted at Pennine in response to COVID-19 2020 • CE mar